Skip to main
ODTX

ODTX Stock Forecast & Price Target

ODTX Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Odyssey Therapeutics is developing innovative medicines targeting important signaling pathways in the innate immune system, with lead program OD-001 showing efficacy and safety in ulcerative colitis (UC) in Phase 1. The company's pipeline also includes candidates targeting other key signaling nodes, offering pipeline diversification and potential for expanded indications. Limited value has yet been attributed to Odyssey's pipeline, and its differentiated approach and potential for combination therapies make it an attractive investment with long-term growth potential.

Bears say

Odyssey Therapeutics is a clinical-stage biopharmaceutical company with high-risk investments in the development of therapies for autoimmune and inflammatory diseases. Failed or delayed trials, typical risks for a company at this stage of maturity, may negatively affect ODTX's stock and balance sheet, with additional risks including maintaining sufficient financial resources, protecting intellectual property, and competition in the market. The limited float and low trading volume of the stock may exacerbate volatility, and the upcoming IPO expiration may drive enhanced volatility. While ODTX's lead candidate, OD-001, is targeting a large market for inflammatory bowel disease, combination treatments and oral small molecules may be well-positioned in the market. The company's other programs targeting TNFR2, IRAK4, and IRF5 have promising potential, but their success is not guaranteed. Additionally, ODTX maintains a number of pending patent applications and intellectual property rights, with potential patent expirations in 2044 to 2045.

ODTX has been analyzed by 3 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Odyssey Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Odyssey Therapeutics Inc (ODTX) Forecast

Analysts have given ODTX a Buy based on their latest research and market trends.

According to 3 analysts, ODTX has a Buy consensus rating as of Jul 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Odyssey Therapeutics Inc (ODTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.